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From 10th to 12th September of 2018, we held the first British Association of Cancer Research (BACR) 
Special Conference on “Response and Resistance in Cancer herapy” at the University of Kent, Canterbury, 
UK. he conference theme is the subject of this Special Issue of Cancer Drug Resistance and we hope this 
editorial and the following contributions, will give you an insight into this important topic.
As we all know, cancer is a major global killer. According to Globocan (http://globocan.iarc.fr/Pages/
fact_sheets_cancer.aspx), there “were 14.1 million new cancer cases, 8.2 million cancer deaths and 32.6 
million people living with cancer (within 5 years of diagnosis) in 2012 worldwide”. Early diagnosis and 
local therapy including surgery and local radiotherapy with or without adjuvant chemotherapy have largely 
accounted for the progress made in curing cancer. Apart from a few exceptions (e.g., testicular cancer, 
Hodgkin’s lymphoma, childhood acute lymphoblastic leukaemia) cure rates remain low for cancers that 
cannot be efectively treated by localised therapy. his is typically metastatic disease, which depends on 
systemic treatment. In such cases, the focus is largely placed on improving and prolonging life
[1-7]
.
It has often been argued that, because the outcome is particularly poor in metastatic disease, pathways 
driving metastasis constitute prime therapeutic targets
[8-10]
. Although it is undoubtedly true that the 
presence of metastases is the number one determinant of poor outcomes in most types of cancer, the 
efficacy of therapeutic targets in this area is much less clear. The vast majority of cancers with poor 
prognosis already present with unresectable, typically metastatic disease at diagnosis, even if the metastases 
cannot be detected at that point
[1,2,4,5]
. In this scenario, inhibition of further metastasis formation may 
prolong life but its curative potential is limited.
Unsatisfactory outcomes of systemic anti-cancer therapies in advanced, metastatic disease have also fuelled 
calls for better strategies for early diagnosis that detect cancer when it is still at a localised, manageable 
stage. However, biomarkers for the timely detection of most cancer types are currently still lacking
[11-14]
. 
Even if reliable biomarkers become available, early recognition may not always improve treatment outcome. 
For example, a mass screening programme for the early detection of neuroblastoma in children using 
vanillylmandelic acid as a biomarker was performed in Japan from 1985 to 2003. However, the programme 
was stopped because it resulted in an increased incidence of neuroblastoma but not in reduced mortality, 
indicating over diagnosis of cases that did not require therapy
[15,16]
. he beneit of mammography-based 
screening programmes for breast cancer is also currently under dispute. Studies suggest that for every 
woman whose life is prolonged through breast cancer screening, ten women receive unnecessary treatment. 
Many women lose subjectively healthy lifetime, because treatment outcome is the same as if therapy had 
started upon the onset of symptoms. False positive results cause anxiety to afected women. Finally, over-
detection, -diagnosis and -treatment of patients who would never have developed a clinically relevant 
disease is an issue
[14,17-20]
.
Of course, we do not dispute the value of understanding metastasis formation, or, of early detection in 
cancer. We simply emphasise that for the foreseeable future, there will be patients who are diagnosed 
with advanced disease that requires systemic therapy. Hence, there is an ongoing need to develop better 
therapies for such patients. The main obstacle to this is resistance. Improved strategies are urgently 
required for those cancers that either fail to respond altogether to treatment (“intrinsic” or “upfront” 
resistance), or stop responding during treatment (“acquired” resistance).
Resistance to anti-cancer therapies is largely a consequence of the small therapeutic window often 
demonstrated by these treatments. The aim of every cancer therapy is to kill all cancer cells or at least 
to permanently stop their proliferation. In contrast to therapies designed to fight single cell pathogens 
(bacteria, fungi, parasites) or viruses, cancer cells are derived from host cells and do not offer specific 
(“foreign”) targets in the same way. Instead they difer in the expression level of genes and the activation 
status of pathways that are also present in normal cells. Hence, therapeutic drug concentrations are 
commonly associated with adverse events. Cytotoxic anti-cancer therapies typically interfere with basic 
cellular processes by inducing DNA damage or targeting the process of cell division. hey are generally 
applied at the “maximum tolerated dose”, which makes further dosage increase impossible. Hence, even 
the formation of low-level resistance results in therapy failure
[21-28]
.
Some protein kinase inhibitors (e.g., first-generation epidermal growth factor receptor and BCR-ABL 
inhibitors) and antibodies interfere more specifically with cancer abnormalities and are characterised 
by better tolerability. However, resistance formation may be an even bigger issue as cures are rare and 
resistance formation often inevitable
[26,27,29-35]
. This may be because it is easier for cancer cells to bypass 
their more selective impact, analogous to the rapid development of resistance to highly speciic antiviral 
therapies; a well-known and recognised phenomenon
[36-39]
.
Immunotherapies, in particular immune checkpoint inhibitors including cytotoxic T lymphocyte associate 
protein-4, programmed cell death 1 (PD-1), and PD-ligand 1, inhibitors have shown great promise for 
subgroups of patients sufering from speciic forms of cancer including melanoma, renal-cell carcinoma, 
non-small-cell lung cancer, and head and neck cancer. Although these therapies are transformative for 
some patients, many do not benefit and long-term responses only occur in a minority of patients. The 
mechanisms underlying these differences are poorly understood, and biomarkers that would predict 
therapy response are lacking. In addition, immune checkpoint inhibitor-based therapies are also associated 
with severe adverse events. Hence, toxicity and resistance are also important issues during the development 
and improvement of such therapies
[40-42]
.
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In conclusion, a lack of response or resistance to anti-cancer therapies, whichever you prefer to call it, 
is the key obstacle that needs to be overcome to improve therapy outcomes in patients diagnosed with 
advanced disease who depend on systemic therapies. You will see from the conference abstracts and the 
contributions to this Special Issue that a wide spectrum of aspects of response and resistance in cancer 
were covered at the conference. We would like to thank all the contributors to this Special Issue and hope 
that you, the reader, will ind the topic and content both interesting and useful. Finally, we encourage you 
to join us at the follow-up 2nd BACR Conference on Response and Resistance in Cancer herapy, which is 
planned for 15th to 17th June 2020 at the University of Kent in Canterbury, UK.
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